Schofield FW . Damaged sweet clover. The cause of a new disease in cattle simulating hemorrhagic septicemia and blackleg. J Am Vet Med Assoc64:553-575, 1924
3.
Link KP . The discovery of dicoumarol and its sequels. Circulation19:97-107, 1959
4.
Lafata JE , Martin SA, Kaatz S, et al. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J General Intern Med15:31-37, 2000
5.
Nutescu EA , Wittkowsky AK. Direct thrombin inhibitors for anticoagulation. Ann Pharmacother38(1):99-109, 2004
6.
Gustafsson D , Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: A mini-review. Thromb Res109:S9-S15, 2003
7.
Crowther MA , Weitz JI. Ximelagatran: The first oral direct thrombin inhibitor. Expert Opin Investig Drugs13(4):403-413, 2004
8.
Francis CW , Berkowitz SD, Comp PC, et al, for the EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after knee replacement. N Engl J Med349:1703-1712, 2003
9.
Schulman S , Wahlander K, Lundstrom T, et al, THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med349(18):1713-1721, 2003
10.
Olsson SB ; Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet362(9397):1691-1698, 2003
11.
Wallentin L , Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomized controlled trial. Lancet362:789-797, 2003
12.
Southworth MR , Bauman JL. Clinical practice in cardiology. In: DiPiro J (ed) Encyclopedia of Clinical Pharmacy. Marcel Dekker, Inc.New York, NY pp 119-126, 2002
13.
Nutescu EA . The future of anticoagulation clinics. J Thromb Thrombolysis16(1-2):61-63, 2003